|
1
|
Chen C, Wu J, Zhu P, Xu C and Yao L:
Investigating isoquinoline derivatives for inhibition of inhibitor
of apoptosis proteins for ovarian cancer treatment. Drug Des Devel
Ther. 11:2697–2707. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang W, Su J, Xu H, Yu S, Liu Y, Zhang Y,
Sun L, Yue Y and Zhou X: Dicumarol inhibits PDK1 and targets
multiple malignant behaviors of ovarian cancer cells. PLoS One.
12:e01796722017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Q, Gao JF and Qi BL: PDCD1 strengthens
the sensitivity of ovarian cancer to cisplatin chemotherapy by
promoting apoptosis. J BUON. 22:746–756. 2017.PubMed/NCBI
|
|
4
|
Zhao Y, Cui L, Pan Y, Shao D, Zheng X,
Zhang F, Zhang H, He K and Chen L: Berberine inhibits the
chemotherapy-induced repopulation by suppressing the arachidonic
acid metabolic pathway and phosphorylation of FAK in ovarian
cancer. Cell Prolif. 50:e123932017. View Article : Google Scholar
|
|
5
|
Zhao SJ, Jiang YQ, Xu NW, Li Q, Zhang Q,
Wang SY, Li J, Wang YH, Zhang YL, Jiang SH, et al: SPARCL1
suppresses osteosarcoma metastasis and recruits macrophages by
activation of canonical WNT/β-catenin signaling through
stabilization of the WNT-receptor complex. Oncogene. 37:1049–1061.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ye H, Wang WG, Cao J and Hu XC: SPARCL1
suppresses cell migration and invasion in renal cell carcinoma. Mol
Med Rep. 16:7784–7790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann
BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, et al:
Yi Y: SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol.
7:1019–1030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu DM, Shi J, Liu T, Deng SH, Han R and Xu
Y: Integrated analysis reveals down-regulation of SPARCL1 is
correlated with cervical cancer development and progression. Cancer
Biomark. 21:355–365. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu X, Gao Y, Zhao B, Li X, Lu Y, Zhang J,
Li D, Li L and Yin F: Discovery of microarray-identified genes
associated with ovarian cancer progression. Int J Oncol.
46:2467–2478. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang G, Yang D, Wang L, Zhang X, Xu H,
Miao Y, Wang E and Zhang Y: A novel biomarker ARMc8 promotes the
malignant progression of ovarian cancer. Hum Pathol. 46:1471–1479.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Josahkian JA, Saggioro FP, Vidotto T,
Ventura HT, Candido Dos Reis FJ, de Sousa CB, Tiezzi DG, de Andrade
JM, Koti M and Squire JA: Increased STAT1 expression in high grade
serous ovarian cancer is associated with a better outcome. Int J
Gynecol Cancer. 28:459–465. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei W, Li Y, Lv S, Zhang C and Tian Y:
PARP-1 may be involved in angiogenesis in epithelial ovarian
cancer. Oncol Lett. 12:4561–4567. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao F, Wang K, Zhu R, Hu YW, Fang WZ and
Ding HZ: Clinicopathological significance of reduced SPARCL1
expression in human breast cancer. Asian Pac J Cancer Prev.
14:195–200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hurley PJ, Hughes RM, Simons BW, Huang J,
Miller RM, Shinder B, Haffner MC, Esopi D, Kimura Y, Jabbari J, et
al: Androgen-regulated SPARCL1 in the tumor microenvironment
inhibits metastatic progression. Cancer Res. 75:4322–4334. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hurley PJ, Marchionni L, Simons BW, Ross
AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z,
et al: Secreted protein, acidic and rich in cysteine-like 1
(SPARCL1) is down regulated in aggressive prostate cancers and is
prognostic for poor clinical outcome. Proc Natl Acad Sci USA.
109:14977–14982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jakharia A, Borkakoty B and Singh S:
Expression of SPARC like protein 1 (SPARCL1), extracellular
matrix-associated protein is down regulated in gastric
adenocarcinoma. J Gastrointest Oncol. 7:278–283. 2016.PubMed/NCBI
|
|
17
|
Bendik I, Schraml P and Ludwig CU:
Characterization of MAST9/Hevin, a SPARC-like protein, that is
down-regulated in non-small cell lung cancer. Cancer Res.
58:626–629. 1998.PubMed/NCBI
|
|
18
|
Naschberger E, Liebl A, Schellerer VS,
Schutz M, Britzen-Laurent N, Kolbel P, Schaal U, Haep L,
Regensburger D, Wittmann T, et al: Matricellular protein SPARCL1
regulates tumor microenvironment-dependent endothelial cell
heterogeneity in colorectal carcinoma. J Clin Invest.
126:4187–4204. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang H, Widegren E, Wang DW and Sun XF:
SPARCL1: A potential molecule associated with tumor diagnosis,
progression and prognosis of colorectal cancer. Tumour Biol.
32:1225–1231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chi F, Wu R, Jin X, Jiang M and Zhu X:
HER2 induces cell proliferation and invasion of non-small-cell lung
cancer by upregulating COX-2 expression via MEK/ERK signaling
pathway. Onco Targets Ther. 9:2709–2716. 2016.PubMed/NCBI
|
|
21
|
Li K, Guo Q, Yang J, Chen H, Hu K, Zhao J,
Zheng S, Pang X, Zhou S, Dang Y and Li L: FOXD3 is a tumor
suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK
signal pathway. Oncotarget. 8:5048–5056. 2017.PubMed/NCBI
|
|
22
|
Shen MJ, Xu LJ, Yang L, Tsai Y, Keng PC
and Chen Y, Lee SO and Chen Y: Radiation alters PD-L1/NKG2D ligand
levels in lung cancer cells and leads to immune escape from NK cell
cytotoxicity via IL-6-MEK/Erk signaling pathway. Oncotarget.
8:80506–80520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Guo X, Xie C and Jiang J: KIF15
promotes pancreatic cancer proliferation via the MEK-ERK signalling
pathway. Br J Cancer. 117:245–255. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Xiao H, Wu H, Yao C, He H, Wang C
and Li W: G protein subunit alpha q regulates gastric cancer growth
via the p53/p21 and MEK/ERK pathways. Oncol Rep. 37:1998–2006.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang K, Gao K, Hu G, Wen Y, Lin C and Li
X: CTGF enhances resistance to 5-FU-mediating cell apoptosis
through FAK/MEK/ERK signal pathway in colorectal cancer. Onco
Targets Ther. 9:7285–7295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang L, Shen M, Xu LJ, Yang X, Tsai Y,
Keng PC, Chen Y and Lee SO: Enhancing NK cell-mediated cytotoxicity
to cisplatin-resistant lung cancer cells via MEK/Erk signaling
inhibition. Sci Rep. 7:79582017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang C, Yu P, Zhu L, Zhao Q, Lu X and Bo
S: Blockade of alpha7 nicotinic acetylcholine receptors inhibit
nicotine-induced tumor growth and vimentin expression in non-small
cell lung cancer through MEK/ERK signaling way. Oncol Rep.
38:3309–3318. 2017.PubMed/NCBI
|
|
28
|
Shen X and Kramer RH: Adhesion-mediated
squamous cell carcinoma survival through ligand-independent
activation of epidermal growth factor receptor. Am J Pathol.
165:1315–1329. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bai RX, Wang WP, Zhao PW and Li CB:
Ghrelin attenuates the growth of HO-8910 ovarian cancer cells
through the ERK pathway. Braz J Med Biol Res. 49:e50432016.
View Article : Google Scholar
|
|
30
|
Bartholomeusz C, Itamochi H, Nitta M, Saya
H, Ginsberg MH and Ueno NT: Antitumor effect of E1A in ovarian
cancer by cytoplasmic sequestration of activated ERK by PEA15.
Oncogene. 25:79–90. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang MC, Chen CA, Chen PJ, Chiang YC,
Chen YL, Mao TL, Lin HW, Lin Chiang WH and Cheng WF: Mesothelin
enhances invasion of ovarian cancer by inducing MMP-7 through
MAPK/ERK and JNK pathways. Biochem J. 442:293–302. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fujisawa T, Joshi BH and Puri RK: IL-13
regulates cancer invasion and metastasis through IL-13Rα2 via
ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J
Cancer. 131:344–356. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ohta T, Isobe M, Takahashi T,
Saitoh-Sekiguchi M, Motoyama T and Kurachi H: The Akt and ERK
activation by platinum-based chemotherapy in ovarian cancer is
associated with favorable patient outcome. Anticancer Res.
29:4639–4647. 2009.PubMed/NCBI
|
|
34
|
Song H, Wei M, Liu W, Shen S, Li J and
Wang L: Cisplatin induced apoptosis of ovarian cancer A2780s cells
by activation of ERK/p53/PUMA signals. Histol Histopathol.
33:73–79. 2018.PubMed/NCBI
|
|
35
|
Su S, Lin X, Ding N, Zhang H, Zhang Q,
Ding Y, Hou X and Tian Y: Effects of PARP-1 inhibitor and ERK
inhibitor on epithelial mesenchymal transitions of the ovarian
cancer SKOV3 cells. Pharmacol Rep. 68:1225–1229. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vergara D, Simeone P, Toraldo D, Del
Boccio P, Vergaro V, Leporatti S, Pieragostino D, Tinelli A, De
Domenico S, Alberti S, et al: Resveratrol downregulates Akt/GSK and
ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol
Biosyst. 8:1078–1087. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang W, Ren F, Wu Q, Jiang D, Li H and Shi
H: MicroRNA-497 suppresses angiogenesis by targeting vascular
endothelial growth factor A through the PI3K/AKT and MAPK/ERK
pathways in ovarian cancer. Oncol Rep. 32:2127–2133. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Al-Ayoubi A, Tarcsafalvi A, Zheng H,
Sakati W and Eblen ST: ERK activation and nuclear signaling induced
by the loss of cell/matrix adhesion stimulates
anchorage-independent growth of ovarian cancer cells. J Cell
Biochem. 105:875–884. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dang JH, Jin ZJ, Liu XJ, Hu D, Wang J, Luo
Y and Li LL: Metformin in combination with cisplatin inhibits cell
viability and induces apoptosis of human ovarian cancer cells by
inactivating ERK 1/2. Oncol Lett. 14:7557–7564. 2017.PubMed/NCBI
|
|
40
|
Chan DW, Hui WW, Cai PC, Liu MX, Yung MM,
Mak CS, Leung TH, Chan KK and Ngan HY: Targeting GRB7/ERK/FOXM1
signaling pathway impairs aggressiveness of ovarian cancer cells.
PLoS One. 7:e525782012. View Article : Google Scholar : PubMed/NCBI
|
